Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Notes Payables (2023 - 2026)

Perspective Therapeutics' Notes Payables history spans 4 years, with the latest figure at $56000.0 for Q1 2026.

  • On a quarterly basis, Notes Payables rose 5.66% to $56000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $56000.0, a 5.66% increase, with the full-year FY2025 number at $56000.0, up 7.69% from a year prior.
  • Notes Payables hit $56000.0 in Q1 2026 for Perspective Therapeutics, roughly flat from $56000.0 in the prior quarter.
  • Over the last five years, Notes Payables for CATX hit a ceiling of $1.8 million in Q2 2023 and a floor of $49000.0 in Q4 2023.
  • Historically, Notes Payables has averaged $316846.2 across 4 years, with a median of $54000.0 in 2024.
  • Biggest five-year swings in Notes Payables: tumbled 97.06% in 2024 and later increased 7.84% in 2025.
  • Tracing CATX's Notes Payables over 4 years: stood at $49000.0 in 2023, then increased by 6.12% to $52000.0 in 2024, then increased by 7.69% to $56000.0 in 2025, then changed by 0.0% to $56000.0 in 2026.
  • Business Quant data shows Notes Payables for CATX at $56000.0 in Q1 2026, $56000.0 in Q4 2025, and $55000.0 in Q3 2025.